Zydus Cadila Covid-19 Vaccine Gets DCGI Approval For Phase-3 Trials
ZyCoV-D was found to be safe, well-tolerated and immunogenic in phase I and II clinical trials, the company said.
PTI 03 January 2021 PTI outlookindia.com 2021-01-03T18:24:21+05:30
Also read
The Drugs Controller General of India (DCGI) has approved conducting phase III trials of the country s first DNA vaccine candidate against Covid-19 being developed by Zydus Cadila, the Department of Biotechnology said on Sunday.
The vaccine candidate has been supported by the National Biopharma Mission (NBM) under the aegis of Biotechnology Industry Research Assistance Council (BIRAC), a PSU under the DBT.